BBI - Brickell Biotech GAAP EPS of -$0.06 beats by $0.03 revenue of $0.1M misses by $0.05M
Brickell Biotech press release (NASDAQ:BBI): Q4 GAAP EPS of -$0.06 beats by $0.03. Revenue of $0.1M (+233.3% Y/Y) misses by $0.05M. The company reported cash and cash equivalents of $26.9M and expects it to support operations beyond the receipt of Phase 1 SAD and MAD topline results for BBI-02, which are anticipated year-end 2022. The company is on track to progress BBI-02, its lead development-stage program, into a Phase 1 clinical trial (BBI-02-101) in Canada in the second quarter of 2022.
For further details see:
Brickell Biotech GAAP EPS of -$0.06 beats by $0.03, revenue of $0.1M misses by $0.05M